Blowout earnings and raised guidance. Ironwood Pharmaceuticals ($IRWD) is dominating the GI market with LINZESS sales up 40% YoY. We analyze why this profitable biotech is a buy despite pipeline delays.
You can't build AI on bad data. Innodata (Nasdaq: INOD) provides the essential RLHF and data engineering for Big Tech's models. With record Q3 revenue and 45%+ projected growth, this is our top AI infrastructure play.
The physical car key is dying. Strattec Security (STRT) is quietly leading the "Smart Access" revolution. With a new CEO and rising margins, this legacy manufacturer is our latest high-conviction long.
